BIIB Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio21.39Forward 14.22
EPS (TTM)$9.2931.1% YoY
Profit margin13.8%HEALTHCARE
Market cap$29.33BLarge cap
Wall Street coverage
$220.13median target· current $225.58 (-2.4%)36 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 14.22
- PEG ratio
- 3.94
- P/B
- 1.57
- P/S (TTM)
- 2.95
- EV/EBITDA
- 11.71
Profitability & growth
- ROE (TTM)
- 7.7%
- Operating margin
- 22.9%
- Revenue growth YoY
- 1.9%
- Dividend yield
- —
- Beta
- 0.18
Last earnings
Apr 29, 2026 · Estimate $2.89 · Reported $3.57
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
21 articles · sorted by datePage 1 of 2 · 21 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Biogen Inc
Company profileBiogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 225 BINNEY STREET, CAMBRIDGE, MA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$29.33B
Shares outstanding$147.6M
52W high$205.97
52W low$121.05
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent